At TrimRx, we have observed how these innovations, when paired with empathetic, personalized care, can help people reclaim their vitality
Study Design: Participants who achieved average 20.9% weight loss on tirzepatide over 36 weeks were randomized to either: Continue tirzepatide Switch to placebo Results at 88 Weeks (52 weeks after randomization): Continued Tirzepatide: Additional 5.5% weight loss Total weight loss: 25.3% from baseline 89.5% maintained at least 80% of initial weight loss Switched to Placebo: 14% weight regain Total weight loss: 9.9% from baseline Only 16.6% maintained at least 80% of initial weight loss Key Takeaway: Continued treatment is essential for maintaining weight loss
Those signals are clinically significant, but retatrutide remains investigational and is not a routine prescription option outside clinical trials
Finally, if you want a prescriptions only approach with minimal involvement, Calibrate may feel overwhelming
Research Directions They are now studying retatrutides weight loss and blood sugar control effects
Allulose, a rare low-calorie sugar, and glucagon-like peptide-1 (GLP-1) receptor agonists represent two distinct approaches to managing blood glucose and weight
